A powerful skin injection is only half of a treatment. The other half happens before the needle — and that half cannot be skipped, only shifted.
You've seen the photos — someone's skin, before and after, transformed in what looks like weeks. The caption says an injection did it. And somewhere nearby, a place is offering to do it soon — no queue, no waiting list, pay and go.
It is tempting for a reason. Some of these injections are real medicine, and for the right person they change lives. The question worth slowing down for is quieter: what happened around that needle — and what it means when nothing did.
What are these injections, actually?
Real prescription medicine, at the strong end of what skin treatment has to offer. A newer class of injectable medicines works by turning down specific parts of the immune system — the parts that drive certain stubborn, immune-driven skin conditions. For people whose condition runs on exactly those pathways, and who are treated in proper care, the results can be genuinely good. Nothing in this article argues against the medicine.
What the medicine cannot do is choose its own patient. That part is done — or not done — by everything that surrounds the needle.
Why do blood tests come before the needle?
Because a medicine that turns down part of the immune system needs to know what it is turning it down over. Some infections can sit quietly in a body for years, held in place by the very defences the injection will soften. The checks that come first — blood work, infection screening, a proper look at your history — are how a prescriber confirms nothing is waiting underneath.
I went looking for where these checks come from, expecting them to be some clinic's house rules — they're not. The specialist guidance for this class of medicine asks for the same screening at the start, for everyone. And the safety record of the newer injections is, on the whole, reassuring — the screening is part of why the record looks the way it does. The checks are not an obstacle in front of the medicine. They are the medicine's own instructions.
If two skin problems look alike, why won't the same injection do?
Because looking alike is not running alike. One kind of trouble weeps and itches in the folds of elbows and knees; another builds sharply-edged, scaly patches on their outer sides — and underneath, the two run on different immune pathways. These injections are built for one pathway. Aimed at the other, the medicine has little to work with, while the body still carries the full weight of having part of its defences turned down.
A key is not less of a key for failing to open the wrong lock. Which is why the first step in proper care is never the needle — it is the naming: finding out which of the look-alikes this actually is.
So what does the shorter path leave out?
Not the needle — everything around it. The injection is one half of what these treatments are. The other half is the part that never appears in a group-chat photo: the naming of the condition, the screening of what the body might quietly be carrying, the follow-up that notices early when something is off. Wherever an injection is offered soon, to anyone, with none of that — the other half has not been made faster. It has not been done. And a half that is not done does not disappear from the treatment. It moves to the person receiving it.
Skin that keeps flaring deserves a name before it gets a needle. That is a conversation for a skin specialist, and it is the one step no photo can stand in for.
The injection is half the treatment. The other half — what the condition is, whether the body is ready, who is watching afterwards — cannot be skipped, only moved onto you. So wherever a needle is offered soon, the question I'd ask first is the quiet one: where is the other half here — and who is going to carry it?
This article is general health information, not medical advice. It is not a guide to diagnosing anyone, and it does not evaluate any specific medicine, clinic or programme. If your skin keeps flaring or is not settling, a skin specialist is the right person to name it — before anyone treats it. Last reviewed: August 2026.
Sources
- Update on TB Screening Prior To and During Biologic Treatment — dermatology clinical review, Practical Dermatology. "All psoriasis patients being considered for biologic treatment require screening at baseline to identify previous exposure to tuberculosis (latent tuberculosis infection, LTBI) or active tuberculosis (TB) infection." On the newer (non-anti-TNF) targeted biologics: "the risk of TB reactivation in patients receiving non-anti-TNF-targeted biologics is negligible" (controlled trials, national registries, postmarketing surveillance) — the reassuring safety record described in this article is calibrated to that finding. Primary guideline: Joint AAD–NPF guidelines of care for the management and treatment of psoriasis with biologics (Menter et al., J Am Acad Dermatol 2019; PMID 30772098) list tuberculosis testing among the baseline evaluations prior to initiating biologic therapy.
- US prescribing information for an IL-17-class biologic (secukinumab; FDA label): "may increase the risk of infections"; "Evaluate patients for active or latent TB infection prior to initiating treatment"; inflammatory bowel disease exacerbations "occurred in COSENTYX treated subjects during clinical trials."
- Guttman-Yassky E, Krueger JG. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum? Current Opinion in Immunology 2017;48:68–73 (PMID 28869867): psoriasis "largely driven by Th17 T-cells and associated IL-17 activation"; atopic dermatitis with "a strong Th2 component associated with IL-4 and IL-13 over-production." Guttman-Yassky E, et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. Journal of Immunology 2008;181(10):7420 (PMID 18981165): "reduced genomic expression of IL-23, IL-17, and IFN-γ in AD compared with psoriasis."